The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum
Open accessAbstract
Thal amyloid phase, which describes the pattern of progressive amyloid-β plaque deposition in Alzheimer's disease, was incorporated into the latest National Institute of Ageing - Alzheimer's Association neuropathologic assessment guidelines. Amyloid biomarkers (positron emission tomography and cerebrospinal fluid) were included in clinical diagnostic guidelines for Alzheimer's disease dementia published by the National Institute of Ageing - Alzheimer's Association and the International Work group. Our first goal was to evaluate the correspondence of Thal amyloid phase to Braak tangle stage and ante-mortem clinical characteristics in a large autopsy cohort. Second, we examined the relevance of Thal amyloid phase in a prospectively-followed autopsied cohort who underwent ante-mortem (11)C-Pittsburgh compound B imaging; using the large autopsy cohort to broaden our perspective of (11)C-Pittsburgh compound B results. The Mayo Clinic Jacksonville Brain Bank case series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-morbidities, and all assigned Thal amyloid phase and Braak tangle stage using thioflavin-S fluorescent microscopy. (11)C-Pittsburgh compound B studies from Mayo Clinic Rochester were available for 35 participants scanned within 2 years of death. Cortical (11)C-Pittsburgh compound B values were calculated as a standard uptake value ratio normalized to cerebellum grey/white matter. In the high likelihood Alzheimer's disease brain bank cohort (n = 1375), cases with lower Thal amyloid phases were older at death, had a lower Braak tangle stage, and were less frequently APOE-ε4 positive. Regression modelling in these Alzheimer's disease cases, showed that Braak tangle stage, but not Thal amyloid phase predicted age at onset, disease duration, and final Mini-Mental State Examination score. In contrast, Thal amyloid phase, but not Braak tangle stage or cerebral amyloid angiopathy predicted (11)C-Pittsburgh compound B standard uptake value ratio. In the 35 cases with ante-mortem amyloid imaging, a transition between Thal amyloid phases 1 to 2 seemed to correspond to (11)C-Pittsburgh compound B standard uptake value ratio of 1.4, which when using our pipeline is the cut-off point for detection of clear amyloid-positivity regardless of clinical diagnosis. Alzheimer's disease cases who were older and were APOE-ε4 negative tended to have lower amyloid phases. Although Thal amyloid phase predicted clinical characteristics of Alzheimer's disease patients, the pre-mortem clinical status was driven by Braak tangle stage. Thal amyloid phase correlated best with (11)C-Pittsburgh compound B values, but not Braak tangle stage or cerebral amyloid angiopathy. The (11)C-Pittsburgh compound B cut-off point value of 1.4 was approximately equivalent to a Thal amyloid phase of 1-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For amyloid imaging, where over a decade of data are available, different ligands, methods of image acquisition, and image processing can result in different thresholds when compared to neuropathologic standards [21,22,196].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies suggest that NFT pathology closely correlates with neurodegeneration and cognitive decline [1, 2].”
From Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“A typical cut point used for 11C Pittsburgh compound B approximately labels individuals with Thal phase 0–1 normal and individuals with Thal phase 2–5 abnormal [21].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Ante-mortem clinical history for age at onset of cognitive symptoms, education, and Mini-Mental State Examination (MMSE) score (Folstein et al., 1975) was retrospectively abstracted from clinical reports for the Mayo Clinic Jacksonville series, with investigators blinded to Thal amyloid phase.”
MethodHirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 4×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
BackgroundMethodInfluentialSelf-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 7×
“A Braak NFT stage of 5IV is consistent with NFTs restricted to limbic regions and not yet involving cortical regions (Braak and Braak, 1991).”
BackgroundMethodInfluentialAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
MethodSelf-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“well as preclinical stages of the disease (Jack et al., 2011; McKhann et al., 2011; Sperling et al., 2011).”
BackgroundMethodSelf-citation
Research works printed but not linked: 1
- 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“A typical cut point used for (11)C Pittsburgh compound B approximately labels individuals with Thal phase 0–1 normal and individuals with Thal phase 2–5 abnormal [21].”
Self-citationAlzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
“Fewer studies have correlated PET with Thal amyloid staging, suggesting earliest detection around stage 1 [66,70].”
BackgroundSelf-citation2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Self-citationAssociation of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., Cosio, D. M. O., Farrell, M., Quiroz, Y. T., Mormino, E. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1424 · Cited by 865
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Self-citationIn vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440
“Particularly the progression from the associative neocortex over primary sensory-motor areas and the medial temporal lobe to the striatum is well-described in the neuropathologic literature and corresponds to phases 1 to 3 of the widely used Thal scheme of 5 progressive phases of cerebral amyloidosis.(2,4) While the f…”
MethodSelf-citationSchwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
Moloney, C. M., Lowe, V. J., & Murray, M. E. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12321 · Cited by 330
Self-citationLa Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
“The independent contribution of Thal phases is consistent with a previous study based on a partly overlapping sample [13] and could reflect [(11)C]PIB binding to fibrillary components of non-neuritic Ab deposits (that are sometimes “diffuse”) that are not captured by the CERAD score [11– 13,21,26].”
BackgroundResultSelf-citationNovak, P., Schmidt, R., Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., Vince-Kazmerova, Z., Katina, S., Fialova, L., Prcina, M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 304
Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia
Lowe, V. J., Wiste, H. J., Senjem, M. L., Weigand, S. D., Therneau, T. M., Boeve, B. F., Josephs, K. A., Fang, P., Pandey, M. K., Murray, M. E., et al. (2018) · Brain · doi:10.1093/brain/awx320 · Cited by 302
“MRI scans at 3 T with a 3D volumetric T1 magnetization-prepared rapid gradient-echo sequence were performed as previously described (Murray et al., 2015; Jack et al., 2017).”
MethodSelf-citationIn vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Stern, Y., & Initiative, A. D. N. (2022) · DZNE Pub · doi:10.7916/0vj1-4c02 · Cited by 289
Progressive inflammation‐mediated neurodegeneration after traumatic brain or spinal cord injury
Faden, A. I., Wu, J., Stoica, B. A., & Loane, D. J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13179 · Cited by 284
“In addition, recent clinical studies have increasingly called into question the role of Aβ as the major driver of cognitive decline in AD patients (Doody et al., 2014; Salloway et al., 2014; Murray et al., 2015).”
BackgroundClearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Mielke, M. M., Vemuri, P., Lowe, V., Senjem, M. L., Gunter, J. L., Reyes, D., et al. (2015) · Brain · doi:10.1093/brain/awv283 · Cited by 254
“40, which was recently validated by autopsy correlation with Thal amyloid phase (Murray et al., 2015).”
BackgroundMethodInfluentialSelf-citationPropagation of prions causing synucleinopathies in cultured cells
Woerman, A. L., Stöhr, J., Aoyagi, A., Rampersaud, R., Krejciova, Z., Watts, J. C., Ohyama, T., Patel, S., Widjaja, K., Oehler, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513426112 · Cited by 247
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
Mielke, M. M., Hagen, C. E., Wennberg, A. M. V., Airey, D. C., Savica, R., Knopman, D. S., Machulda, M. M., Roberts, R. O., Jack, C. R., Petersen, R. C., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1359 · Cited by 211
Self-citationAPOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology
Dickson, D. W., Heckman, M. G., Murray, M. E., Soto, A. I., Walton, R. L., Diehl, N. N., van Gerpen, J. A., Uitti, R. J., Wszolek, Z. K., Ertekin-Taner, N., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006212 · Cited by 210
Self-citationCarvalho, D. Z., St Louis, E. K., Knopman, D. S., Boeve, B. F., Lowe, V. J., Roberts, R. O., Mielke, M. M., Przybelski, S. A., Machulda, M. M., Petersen, R. C., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0049 · Cited by 203
“4 has beenproposed to be a reliable cutoff to select participants in whom Aβ accumulation is more like likely to occur(44) and corresponds to Thal amyloid phases of at least 1 to 2.(45) Conversion of PiB was defined as global PiB SUVR at second scan of at least 1.”
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 202
Self-citationJack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., et al. (2019) · Brain · doi:10.1093/brain/awz268 · Cited by 200
“Third, cut points for amyloid PET have been validated against neuropathology (Murray et al., 2015; La Joie et al., 2019).”
Self-citationNovak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00070-2 · Cited by 187
AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Boeve, B. F., Senjem, M. L., Tosakulwong, N., Lesnick, T. G., Spychalla, A. J., Gunter, J. L., Fields, J. A., Graff‐Radford, J., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24825 · Cited by 181
Self-citationTau Protein and Its Role in Blood–Brain Barrier Dysfunction
Michalicova, A., Majerova, P., & Kovac, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.570045 · Cited by 177
“Moreover, the distribution and load of neurofibrillary pathology is correlated with clinical phenotype and severity of cognitive impairment (Nelson et al., 2012; Murray et al., 2015).”
BackgroundRecent update on the heterogeneity of the Alzheimer’s disease spectrum
Jellinger, K. A. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02449-2 · Cited by 169
Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168
“…upstream of tau pathology (Oddo et al., 2003; Small and Duff, 2008), growing evidence indicates that tau pathology drives cognitive decline in AD (Murray et al., 2015), providing an explanation for the lack of connection between the staging of amyloid plaques Frontiers in Cellular Neuroscience |…”
BackgroundJosephs, K. A., Murray, M. E., Tosakulwong, N., Whitwell, J. L., Knopman, D. S., Machulda, M. M., Weigand, S. D., Boeve, B. F., Kantarci, K., Petrucelli, L., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1681-2 · Cited by 168
Self-citationMitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer’s Disease
Cabezas-Opazo, F., Vergara-Pulgar, K., Maria Jose Perez, J., Jara, C., Osorio‐Fuentealba, C., & Quintanilla, R. A. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/509654 · Cited by 167
“At the same time, tau pathology has a profound effect on neuronal health, affecting different processes such as transport, autophagy, and neuronal communication [2], and recent studies suggest a major role in the progression of AD [3].”
BackgroundLocal and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S. L., Bejanin, A., Boxer, A. L., Gorno-Tempini, M. L., Janabi, M., Kramer, J. H., Lazaris, A., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.09.016 · Cited by 165
Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 160
Self-citationStefanovski, L., Triebkorn, P., Spiegler, A., Díaz-Cortés, M.-A., Solodkin, A., Jirsa, V., McIntosh, A. R., Ritter, P., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00054 · Cited by 158
The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases
Nelson, P. T., Abner, E. L., Patel, E., Anderson, S., Wilcock, D. M., Kryscio, R. J., Eldik, L. J. V., Jicha, G. A., Gal, Z. T., Nelson, R. S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx099 · Cited by 154
Knopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R. A., Maruff, P. T., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 154
Self-citationMesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Staff, N. P., Jones, D. T., & Singer, W. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.001 · Cited by 150
PET staging of amyloidosis using striatum
Hanseeuw, B. J., Betensky, R. A., Mormino, E. C., Schultz, A. P., Sepulcre, J., Becker, J. A., Jacobs, H. I. L., Buckley, R. F., LaPoint, M. R., Vannini, P., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.04.011 · Cited by 149
“We also did not assess allocortical Ab because Thal Phase 2 appears difficult to identify using PET [30,31].”
BackgroundSelective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Maphis, N., Jiang, S., Xu, G., Kokiko-Cochran, O. N., Roy, S. M., Van Eldik, L. J., Watterson, D. M., Lamb, B. T., & Bhaskar, K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0221-y · Cited by 147
“…of the major pathological hallmarks of AD and related tauopathies, occurs when microtubule-associated protein tau (MAPT or tau) undergoes hyper-phosphorylation and aggregates as NFTs. Recent studies suggest that NFT pathology closely correlates with neurodegeneration and cognitive decline [1, 2].”
Hou, X., Fiesel, F. C., Truban, D., Castanedes Casey, M., Lin, W.-L., Soto, A. I., Tacik, P., Rousseau, L. G., Diehl, N. N., Heckman, M. G., et al. (2018) · Autophagy · doi:10.1080/15548627.2018.1461294 · Cited by 147
Self-citationDage, J. L., Wennberg, A. M. V., Airey, D. C., Hagen, C. E., Knopman, D. S., Machulda, M. M., Roberts, R. O., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.001 · Cited by 145
Self-citationAβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain
Aoyagi, A., Condello, C., Stöhr, J., Yue, W., Rivera, B. M., Lee, J. C., Woerman, A. L., Halliday, G. M., van Duinen, S. G., Ingelsson, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8462 · Cited by 144
“The latter hypothesis is supported by the correlation of increasing AD severity with the spread of A throughout the brain (27, 28) and decreased A42 in cerebrospinal fluid (CSF) (29).”
InfluentialFluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140
APOE ε2 is associated with increased tau pathology in primary tauopathy
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06783-0 · Cited by 139
Self-citationAlzheimer's disease: The next frontier—Special Report 2017
Karlawish, J. H., Jack, C. R., Rocca, W. A., Snyder, H. M., & Carrillo, M. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.006 · Cited by 135
Self-citationDi, J., Cohen, L. S., Corbo, C. P., Phillips, G. R., Idrissi, A. E., & Alonso, A. D. C. (2016) · Scientific Reports · doi:10.1038/srep20833 · Cited by 132
Microglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
“When patients present with mild cognitive impairment, their PET signals are near maximal and correlate poorly with the degree of cognitive impairment (10,132,133).”
Novák, P., Žilka, N., Žilková, M., Kováčech, B., Škrabana, R., Ondrus, M., Fialová, L., Kontseková, E., Otto, M., & Novák, M. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.45 · Cited by 131
“Long neglected by a large portion of the AD field and seen as a by-product of amyloid β pathology, neurofibrillary tau pathology has been established as the closest correlate of cortical atrophy (5) and clinical progression in AD (6-8).”
Jack, C. R., Therneau, T. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Mielke, M. M., Vemuri, P., Roberts, R. O., Machulda, M. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00323-3 · Cited by 129
Self-citationSex and age interact to determine clinicopathologic differences in Alzheimer’s disease
Liesinger, A. M., Graff-Radford, N. R., Duara, R., Carter, R. E., Hanna Al-Shaikh, F. S., Koga, S., Hinkle, K. M., DiLello, S. K., Johnson, M. F., Aziz, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1908-x · Cited by 126
“Standard methods for genetic screening of APOE and MAPT were used, as previously described [24, 25].”
Self-citationAmyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 125
Serrano‐Pozo, A., Qian, J., Muzikansky, A., Monsell, S. E., Montine, T. J., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw026 · Cited by 120
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
“In addition, tau was found to potentially play a role in early AD pathology [74,80], and immune and lipid metabolism pathways may be involved.”
BackgroundMethodA brief history of “Alzheimer disease”: Multiple meanings separated by a common name
Knopman, D. S., Petersen, R. C., & Jack, C. R. (2019) · Neurology · doi:10.1212/wnl.0000000000007583 · Cited by 118
“PET imaging of β-amyloid has been validated neuropathologically as a diagnostic biomarker.(47,48) CSF studies of β-amyloid42 reasonably closely approximated amyloid PET measures (especially in a ratio with tau or β-amyloid40) and provided ameasure of concurrent validity.”
MethodSelf-citationβ-Amyloid PET and neuropathology in dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Chen, Q., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Jack, C. R., Graff‐Radford, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008818 · Cited by 117
Self-citationFerman, T. J., Aoki, N., Crook, J. E., Murray, M. E., Graff‐Radford, N. R., van Gerpen, J. A., Uitti, R. J., Wszołek, Z. K., Graff‐Radford, J., Pedraza, O., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.09.014 · Cited by 115
Self-citationPost-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
Ikonomović, M. D., Buckley, C. J., Heurling, K., Sherwin, P. F., Jones, P. A., Zanette, M., Mathis, C. A., Klunk, W. E., Chakrabarty, A., Ironside, J. W., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0399-z · Cited by 114
Is amyloid-β harmful to the brain? Insights from human imaging studies
Jagust, W. (2016) · Brain · doi:10.1093/brain/awv326 · Cited by 110
APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, C.-C., Murray, M. E., Li, X., Zhao, N., Wang, N., Heckman, M. G., Shue, F., Martens, Y., Li, Y., Raulin, A.-C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9375 · Cited by 108
Self-citationEntorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects
Knopman, D. S., Lundt, E. S., Therneau, T. M., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., Machulda, M. M., et al. (2019) · Brain · doi:10.1093/brain/awz025 · Cited by 108
Self-citationAβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöhr, J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 108
“Most moderate to late-stage AD patients show unambiguous amyloid positive PET scans (Klunk et al. 2004, Murray et al. 2015), but a minority of these cases appear negative despite biomarker and behavioral measures consistent with AD diagnosis (Rosen et al. 2010, Johnson et al. 2013, Landau et…”
Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias
Turner, R. S., Stubbs, T., Davies, D. A., & Albensi, B. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00496 · Cited by 107
“The current biomarker measures are not sensitive to low but perhaps clinically significant levels of early pathology (13, 14).”
BackgroundLiu, W., Wong, A., Au, L. W. C., Yang, J., Wang, Z., Leung, E. Y. L., Chen, S., Ho, C. L., & Mok, V. (2015) · Stroke · doi:10.1161/strokeaha.115.010449 · Cited by 107
“It suggests that Aβ deposition may have an independent and lasting effect on cognition or more likely, Aβ keeps modulating cognition indirectly by triggering a cascade of downstream events, such as tau formation, glial activation, synaptic dysfunction, and neuronal loss.(19) In our study, different trajectories on cog…”
BackgroundGenetic variants in Alzheimer disease — molecular and brain network approaches
Gaiteri, C., Mostafavi, S., Honey, C. J., Jager, P. L. D., & Bennett, D. A. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.84 · Cited by 103
APOE ɛ4 dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction
Uchida, Y., Kan, H., Sakurai, K., Horimoto, Y., Hayashi, E., Iida, A., Okamura, N., Oishi, K., & Matsukawa, N. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328519 · Cited by 103
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Moore, K. B. E., Hung, T.-J., & Fortin, J. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103487 · Cited by 98
Krell‐Roesch, J., Vassilaki, M. E., Mielke, M. M., Kremers, W. K., Lowe, V. J., Vemuri, P., Machulda, M. M., Christianson, T. J. H., Syrjanen, J. A., Stokin, G. B., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0456-z · Cited by 96
Self-citationEpigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons
Chesser, A. S., Ganeshan, V. R., Yang, J., & Johnson, G. V. W. (2015) · Nutritional Neuroscience · doi:10.1179/1476830515y.0000000038 · Cited by 95
Kell, D. B., & Pretorius, E. (2016) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.08.006 · Cited by 95
Crist, A. M., Hinkle, K. M., Wang, X., Moloney, C. M., Matchett, B. J., Labuzan, S. A., Frankenhauser, I., Azu, N. O., Liesinger, A. M., Lesser, E. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22399-3 · Cited by 94
Self-citationNeuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, V. J., Lundt, E. S., Albertson, S. M., Przybelski, S. A., Senjem, M. L., Parisi, J. E., Kantarci, K., Boeve, B., Jones, D. T., Knopman, D., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.016 · Cited by 90
“We previously showed the association of Thal amyloid phase and amyloid-PET [36].”
Self-citationChang, W., Huang, D., Lo, Y.-M. M., Tee, Q., Kuo, P., Wu, J. S., Huang, W., & Shen, S. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b02078 · Cited by 89
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 89
Self-citationTen Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, P., Kontsekova, E., Zilka, N., & Novak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00798 · Cited by 87
“Recent large-scale studies have revealed the close correlation between tau lesions and progression of neurodegenerative disease (Nelson et al., 2012; Murray et al., 2015).”
BackgroundSalloway, S., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.06.001 · Cited by 87
“[30] who used the research tracer [(11)C]PiB to compare autopsy findings with PET image results.”
Self-citationKrell‐Roesch, J., Lowe, V. J., Neureiter, J., Pink, A., Roberts, R. O., Mielke, M. M., Vemuri, P., Stokin, G. B., Christianson, T. J. H., Jack, C. R., et al. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217002368 · Cited by 87
Self-citationDiagnostic Accuracy of Amyloid versus FDG PET in Patients with Cognitive Impairment and Autopsy
Lesman‐Segev, O. H., Joie, R. L., Iaccarino, L., Lobach, I. V., Rosen, H. J., Seo, S. W., Janabi, M., Baker, S. L., Edwards, L., Pham, J. Q., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25968 · Cited by 85
Chiotis, K., Saint‐Aubert, L., Boccardi, M., Gietl, A. F., Picco, A., Varrone, A., Garibotto, V., Herholz, K., Nobili, F. M., Nordberg, A. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.012 · Cited by 84
Self-citationKoga, S., Kouri, N., Walton, R. L., Ebbert, M., Josephs, K. A., Litvan, I., Graff‐Radford, N. R., Ahlskog, J. E., Uitti, R. J., van Gerpen, J. A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1878-z · Cited by 83
“Braak neurofibrillary tangle (NFT) stage and Thal amyloid phase were assigned based upon lesion density and distribution with thioflavin S fluorescent microscopy according to published criteria [6, 45, 46, 55].”
Self-citationPhysiological and Pathophysiological Implications of Synaptic Tau
Regan, P. L., Whitcomb, D. J., & Cho, K. (2016) · The Neuroscientist · doi:10.1177/1073858416633439 · Cited by 82
“Although amyloid pathology precedes this tau pathology in AD patients, correlative studies have shown that it is the extent of tau pathology that closely mirrors, and appears to dictate the extent of, neuronal loss and cognitive decline (Nelson and others, 2012; Murray and others, 2015).”
BackgroundHou, X., Watzlawik, J. O., Cook, C. N., Liu, C., Kang, S. S., Lin, W., Deture, M. A., Heckman, M. G., Diehl, N. N., Al‐Shaikh, F. S. H., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12198 · Cited by 80
Self-citationFluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α‐synuclein pathology
Koga, S., Ono, M., Sahara, N., Higuchi, M., & Dickson, D. W. (2017) · Movement Disorders · doi:10.1002/mds.27013 · Cited by 76
Self-citationAlzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 74
Tabatabaei‐Jafari, H., Walsh, E., Shaw, M. E., Cherbuin, N., & Initiative, A. D. N. (2017) · Human Brain Mapping · doi:10.1002/hbm.23580 · Cited by 71
“It is also consistent with the chronological development of AD pathology with progressive spreading of tau fibrillatory tangles (Braak stages), amyloid deposition, and subsequently gradual decline in cognitive function [Murray et al., 2015].”
ResultHeckman, M. G., Brennan, R. R., Labbé, C., Soto, A. I., Koga, S., Deture, M. A., Murray, M. E., Petersen, R. C., Boeve, B. F., van Gerpen, J. A., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0250 · Cited by 69
Self-citationClinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome
Sakae, N., Josephs, K. A., Litvan, I., Murray, M. E., Duara, R., Uitti, R. J., Wszołek, Z. K., van Gerpen, J. A., Graff‐Radford, N. R., & Dickson, D. W. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.04.011 · Cited by 69
“Braak NFT stages and Thal amyloid phases were assigned to each case based on lesion counts in cortical and subcortical areas by thioflavin S fluorescent microscopy [33].”
MethodSelf-citationAshford, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150381 · Cited by 68
“Further, A levels in the brain do not predict the age at onset, disease duration, or dementia severity [43].”
BackgroundS tudy of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration
Sánchez-Contreras, M., Heckman, M. G., Tacik, P. M., Diehl, N. N., Brown, P. H., Soto‐Ortolaza, A. I., Christopher, E. A., Walton, R. L., Ross, O. A., Golbe, L. I., et al. (2016) · Movement Disorders · doi:10.1002/mds.26815 · Cited by 68
Self-citationNeuroimaging biomarkers and impaired olfaction in cognitively normal individuals
Vassilaki, M. E., Christianson, T. J. H., Mielke, M. M., Geda, Y. E., Kremers, W. K., Machulda, M. M., Knopman, D. S., Petersen, R. C., Lowe, V. J., Jack, C. R., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24960 · Cited by 68
Self-citationThe Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging
Fantoni, E., Collij, L. E., Alves, I. L., Buckley, C. J., & Farrar, G. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235879 · Cited by 67
Hessen, E., Eckerström, M., Nordlund, A., Almdahl, I. S., Stålhammar, J., Bjerke, M., Eckerström, C., Göthlin, M., Fladby, T., Reinvang, I., et al. (2017) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000454676 · Cited by 66
An Algorithm for Preclinical Diagnosis of Alzheimer's Disease
Khan, T. K. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00275 · Cited by 66
Subthreshold amyloid and its biological and clinical meaning: Long way ahead
Bischof, G. N., & Jacobs, H. I. L. (2019) · Neurology · doi:10.1212/wnl.0000000000007747 · Cited by 66
Thal, D. R., Beach, T. G., Zanette, M., Lilja, J., Heurling, K., Chakrabarty, A., Ismail, A., Farrar, G., Buckley, C. J., & Smith, A. P. L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1897-9 · Cited by 65
“[27] reported that even Aβ-phase 1 cases could be identified by amyloid PET but they used a different PET-ligand and a different protocol for the neuropathological assessment of the Aβ-phases, especially a different staining technique, that makes it difficult to compare their results with ours using another presumably…”
BackgroundMethodResultInfluential
Metadata
- Authors
- Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., Ross, O. A., Duara, R., Knopman, D. S., Jack, C. R., & Dickson, D. W.
- Affiliations
- Mayo Clinic (US)
- University of Miami (US)
- Corresponding author
- Murray, Melissa E.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-23
- Volume
- 138
- Issue
- 5
- Pages
- 1370-1381
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC4407190
- OpenAlex
- W2148457471
- Cited by
- 324
- References
- 72
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 15 · 2022: 18 · 2021: 32 · 2020: 38 · 2019: 41 · 2018: 34 · 2017: 36 · 2016: 35 · 2015: 25
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institute on Aging (R01AG040042, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P50NS072187)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, 11C-Pittsburgh compound B, amyloid PET, amyloid plaques, APOE ε4, cerebral amyloid angiopathy, thioflavin S staining, age of onset, disease duration, amyloid biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Female, Humans, Male, Middle Aged, Thiazoles, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.